TrialPath

Find a study

Match me to a study

366 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidney

143 studies on the map

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight — AMR Clinical, MobileA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain — MD First Research - Chandler, ChandlerAMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss — Pinnacle Research Group LLC, AnnistonA Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease — N America Res Inst - San Dimas, San DimasStudy of ALTO-300 in MDD — Site 200, PhoenixA Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Arizona Research Center, Inc., PhoenixA Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight — Cullman Clinical Trials, CullmanA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Pinnacle Research Group, AnnistonAMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain — Neighborhood Healthcare, EscondidoEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Headlands Research, ScottsdaleA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes — Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, GilbertMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanA Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — MFA Clinical Research, TuscaloosaAMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Dignity Health, Mercy Gilbert, GilbertMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight — Neighborhood Healthcare, EscondidoAMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight — Univ of Alabama Birmingham, BirminghamConvergent Mechanisms Underlying Reprometabolic Syndrome in Women — University of Colorado School of Medicine, AuroraMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy — Valley Clinical Trials, NorthridgeNeurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD — Emory Clinic, AtlantaA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes — Birmingham Clinical Research, BirminghamA Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Advanced Cardiovascular, LLC, Alexander CityA Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin — Birmingham Clinical Research, BirminghamEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Alliance For Multispecialty Research - Daphne, DaphneA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — CenExel Anaheim Clinical Trials, AnaheimAMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea — Artemis Insitute for Clin Res, San DiegoEfficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes — Kailera Clinical Site, AnnistonAMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight — South Broward Research LLC, MiramarA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) — Carey Chronis MD Pediatric, Infant and Adolescent Medicine, VenturaA Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Lakeview Clinical Research, GuntersvilleA Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) — Arizona Clinical Trials-Chandler, ChandlerA Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight — The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, ChandlerEfficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH) — Cahaba Research, Inc., PelhamA Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities — Carey Chronis MD Pediatric, Infant and Adolescent Medicine, VenturaMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — University of Alabama Saint Vincent's Birmingham, BirminghamA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight — Uni of Alabama at Birmingham, BirminghamEfficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes — Kailera Clinical Site, CullmanStudy to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease — Apogee Clinical Research, LLC, HuntsvilleProact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Nephrology Consultants, HuntsvilleA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Apogee Clinical Research, HuntsvilleA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria — Phoenix Children's Hospital | Main - Transplant Department, PhoenixA Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease — Research Site, DecaturA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) — University of Alabama at Birmingham, BirminghamA Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria — Phoenix Children's Hospital | Main - Transplant Department, PhoenixA Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China — Renal Consultants Medical Group, Granada HillsA Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis — Childrens Hospital of Los Angeles, Los AngelesA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, Tucson"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" — Scottsdale Research Institute, PhoenixMulticenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients — Harmonex Neuroscience Research, DothanA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder — IMA Clinical Research Phoenix, PhoenixA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder — UAB Psychiatry and Behavioral Neurology, BirminghamA Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Harmonex Neuroscience Research, DothanA Study of Brenipatide in Adult Participants With Major Depressive Disorder — Accellacare - Moorpark, MoorparkALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamE-Mindfulness Approaches for Living After Breast Cancer — Mayo Clinic Hospital in Arizona, PhoenixA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. — Pillar Clinical Research /ID# 226504, BentonvilleLong-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, OceansidePhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — University of Alabama at Birmingham, BirminghamStudy of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — University of Alabama at Birmingham, HuntsvilleEvaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder — Vanda Investigational Site, PhoenixEfficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes — Kailera Clinical Site, GlendaleZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, ChinoA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia — R1 Therapeutics Clinical Trial Site, HuntsvilleA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamA Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Noble Clinical Research, TucsonALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerA Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) — Lighthouse Psychiatry, GilbertA Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight — Arizona Clinical Trials, ChandlerEfficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity — Kailera Clinical Site, ChandlerA Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM — Clinical Trial Site, MontclairA Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD) — Memorial Healthcare System, HollywoodACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamCaloric Restriction and Activity to Reduce Chemoresistance in B-ALL — Children's Hospital Los Angeles, Los AngelesFerric Citrate and Chronic Kidney Disease in Children — University of California, Los Angeles, Los AngelesSotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease — Stanford University Medical Center, StanfordSafety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD — Clinical Trial Site, San FranciscoOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy. — Colorado Kidney Care Nephrology, DenverStudy to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, Little RockA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — CI Trials, BellflowerProof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss — DM Clinical Research - Phoenix, PhoenixA Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors — Site 108, ChandlerClinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Clinical Research Site, ChinoA Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity — Parexel International-EPCU Baltimore, BaltimoreEvaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events — Diablo Clinical Research, Inc., Walnut CreekA Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) — University of Alabama, BirminghamA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) — Mayo Clinic in Arizona, ScottsdaleA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use — Vanda Investigational Site, Los AngelesSAfety of Regional Citrate Anticoagulation (SARCA Study) — John L. McClellan Memorial Veterans' Hospital, Little RockNBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — Neurocrine Clinical Site, HuntsvilleA Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity — ClearVue Eye Care, RosevilleSafety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant — University of Cincinnati, CincinnatiCSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes — VA Long Beach Healthcare System, Long Beach, CA, Long BeachA Study of LY3971297 in Healthy Participants — CenExel ACT, AnaheimA Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment — UAB Pediatric Endocrinology (Part C and Part D), BirminghamREgulatory T Cell Therapy to Achieve Immunosuppression REduction — Mayo Clinic in Arizona, PhoenixPCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study — Mood Institute, MilfordA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort — Research Site, GlendaleStudy of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma — Stanford, Palo AltoA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity — MBX Biosciences Investigational Site, DoralShingrix in Renal Transplant Recipients — University of Colorado Anschutz, AuroraCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookEffect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachA Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity — Fortrea Clinical Research Unit - Daytona Beach, Daytona BeachA Study of LY4064912 in Healthy Participants and With Overweight or Obesity — Collaborative Neuroscience Network - CNS, Los AlamitosA Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity. — Research Site, GlendaleStudy of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) — Qps-Mra, Llc., MiamiA Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006) — Panax Clinical Research ( Site 0003), Miami LakesNeurovascular Transduction During Exercise in Chronic Kidney Disease — Emory University Hospital Midtown, AtlantaOxytocin for Weight Loss in Adolescents — Massachusetts General Hospital, BostonModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimoreA Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity — Altasciences Clinical LA, Inc., CypressMechanisms of Semaglutide Therapy in Heart Failure Patients — Greenstone Biosciences, Palo AltoA Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. — Monroe Biomedical Research, LouisvilleA Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity — CenExel ACT- Anaheim Clinical Trials /ID# 283200, AnaheimEfficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity — The Children's Hospital of Philadelphia, PhiladelphiaA Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets — Corxel Investigational site, Las VegasSemaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation — The University of Arizona College of Medicine- Phoenix, PhoenixA Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet — Advent Health-Res Inst, OrlandoSit Less, Interact and Move More (SLIMM) 2 Study — Stanford University, StanfordStudy of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D — Clinical Pharmacology of Miami, MiamiA Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy — Fortrea Clinical Research Unit, MadisonA Study on How NNC0174-1213 Works in People With Overweight or Obesity. — ICON Early Phase Services, LLC, San AntonioTesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV — University of Colorado - Anschutz Medical Campus, AuroraSocial Determinants and a Diabetes Prevention Program Tailored for African Americans — University Health, Kansas CitySemaglutide for Post-Smoking Cessation Weight Management — The University of Texas at Austin, AustinUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonInvestigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism — Biomedical Research Imaging Center Marsico Hall (UNC), Chapel HillPhentermine's Impact on Treatment in Teens — University of New Mexico Health Sciences Center, AlbuquerqueBone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine, The BronxSafety and Efficacy of Empagliflozin in Hemodialysis — Brigham and Women's Hospital, BostonA Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function — Floridian Clinical Research, LLC, Miami Lakes

Showing the 150 nearest — narrow your filters for fewer, closer studies.